Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.67 ▼ -0.03
(-4.29%)
MKT CAP: $2.5M • VOL: 20.9K
52W L $1 52W H $27
ROARABLE / RQD
D- • 41/100
PIOTROSKI
2 / 9
CLDI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$20.2M | -$21.8M | -$29.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$19.9M | -$22.1M | -$29.2M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$21.3M | -$19.7M | -$27.0M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$21.3M | -$19.7M | -$27.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | — | $9.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $3.8M | $1.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CLDI.